EGFR and lung carcinoma: No difference in the number of tumors at 3 months postinduction (Fig. 1l) or in overall survival (Fig. 1m) was observed in EP versus EPA3B mice, suggesting that A3B expression is tolerated in a p53-deficient model of EGFR-driven lung cancer.